Table 2.

Real-world studies on vedolizumab in patients with inflammatory bowel disease, Crohn’s disease, or ulcerative colitis

Study author (country) years	IBD	CD	UC
Amiot et al[15,16] (France), 2016-2017	294	173	121
Eriksson et al[19] (Sweden), 2017	246	147	991
Baumgart et al[17] (Germany), 2016	212	97	115
Dulai et al[23] (United States, multicentre), 2016	212	212	-
Kopylov et al[20] (Israel), 2017	204	130	741
Shelton et al[24] (United States, Boston), 2015	172	107	651
Macaluso et al[22] (Italy, Sicily), 2018	163	84	79
Allegretti et al[26] (United States, Boston), 2017	136	96	40
Stallmach et al[18] (German Registry), 2016	127	67	60
Vivio et al[25] (United States, Saint Louis), 2016	102 (51)2	30	21
Samaan et al[21] (United Kingdom), 2017	50	27	231
Total	1.918	1.170	697

¹UC + IBD unclassified;

²102 patients started vedolizumab, and 51 patients were followed prospectively. IBD: Inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative colitis.